Literature DB >> 631898

Amphotericin B concentrations in saliva after application of 2% amphotericin B in orabase.

H G de Vries-Hospers, D van der Waaij.   

Abstract

2% amphotericin B in orabase was applied to the buccal mucous membranes of healthy volunteers. Amounts of 1 g and 0.5 g were used. The experiments were performed during the day time as well as during the sleeping hours at night. At several intervals after application saliva samples were collected and the amphotericin B concentrations were determined. Application of 1 g of orabase with 2% amphotericin B appears to maintain a sufficiently high concentration for four hours, 0.5 g for three hours. Application of these amounts before going to sleep guarantees a sufficient concentration until awakening the next morning.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 631898     DOI: 10.1007/bf01641085

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  8 in total

1.  Nystatin.

Authors:  B DOBIAS; E L HAZEN
Journal:  Chemotherapia (Basel)       Date:  1961

2.  Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukemia patients. I: clinical results.

Authors:  M Dietrich; W Gaus; J Vossen; D van der Waaij; F Wendt
Journal:  Infection       Date:  1977       Impact factor: 3.553

Review 3.  Analysis and assay of polyene antifungal antibiotics. A review.

Authors:  A H Thomas
Journal:  Analyst       Date:  1976-05       Impact factor: 4.616

4.  Infectious complications in cancer patients treated with chemical immunosuppressive agents.

Authors:  D Armstrong
Journal:  Transplant Proc       Date:  1973-09       Impact factor: 1.066

5.  Reduction of supragingival plaque accumulations in institutionalized Down's syndrome patients by periodic treatment with topical kanamycin.

Authors:  W J Loesche; D Nafe
Journal:  Arch Oral Biol       Date:  1973-09       Impact factor: 2.633

6.  Evaluation of an automatic diluting device for microbiological applications.

Authors:  W A Goss; E B Cimijotti
Journal:  Appl Microbiol       Date:  1968-09

7.  Septicaemia in acute leukaemia.

Authors:  M A Burgess; G C de Gruchy
Journal:  Med J Aust       Date:  1969-05-31       Impact factor: 7.738

8.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

  8 in total
  4 in total

1.  Clinical use of selective decontamination: the concept.

Authors:  D van der Waaij; W L Manson; J P Arends; H G de Vries-Hospers
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

2.  The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients.

Authors:  H G de Vries-Hospers; N H Mulder; D T Sleijfer; H K van Saene
Journal:  Infection       Date:  1982       Impact factor: 3.553

3.  E.O.R.T.C. Gnotobiotic Project Group: a prospective cooperative study of antimicrobial decontamination in granulocytopenic patients. Comparison of two different methods.

Authors: 
Journal:  Infection       Date:  1982       Impact factor: 3.553

4.  Salivary concentrations of amphotericin B following its use as an oral lozenge.

Authors:  H G de Vries-Hospers; D van der Waaij
Journal:  Infection       Date:  1980       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.